Granulocyte macrophage-colony stimulating factor (GM-CSF) and sucralfate in prevention of radiation-induced mucositis: A prospective randomized study

International Journal of Radiation Oncology Biology Physics

Volumn 46, Issue 3, 2000, Pages 525-534

  Makkonen, Tuula A ^a   Minn, Heikki ^b   Jekunen, Antti ^e   Vilja, Pekka ^c   Tuominen, Juhani ^d   Joensuu, Heikki ^e  

^a UNIVERSITY OF TURKU   (Finland)

^b TURKU UNIVERSITY HOSPITAL   (Finland)

^c TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^d UNIVERSITY OF TURKU   (Finland)

^e HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

Head and neck cancer; Molgramostim; Mucositis; Radiotherapy; Sucralfate

Indexed keywords

GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; LACTOFERRIN; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; SUCRALFATE;

ADULT; AGED; ARTICLE; BONE PAIN; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; FEMALE; HEAD CANCER; HUMAN; MALE; MOUTH HYGIENE; MUCOSA INFLAMMATION; NAUSEA; NECK CANCER; PRIORITY JOURNAL; RADIATION INJURY; RANDOMIZED CONTROLLED TRIAL; SKIN MANIFESTATION; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; ANTI-ULCER AGENTS; ANTIFUNGAL AGENTS; BIOLOGICAL MARKERS; DOSE FRACTIONATION; FEMALE; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; INJECTIONS, SUBCUTANEOUS; LACTOFERRIN; LEUKOPENIA; MALE; MIDDLE AGED; PAIN MEASUREMENT; PATIENT SELECTION; PROSPECTIVE STUDIES; RADIATION INJURIES; RADIATION-PROTECTIVE AGENTS; SALIVA; STOMATITIS; SUCRALFATE;

EID: 0033982779     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0360-3016(99)00452-6     Document Type: Article

References (47)

1. Horiot J.C., Le Fur R., N'Guyen T., et al. Hyperfractionation versus conventional fractionation in oropharyngeal carcinoma Final analysis of a randomized trial of the EORTC cooperative group of radiotherapy . Radiother Oncol. 25:1992;231-241.
2. Leslie M.D., Dische S. The early changes in salivary gland function during and after radiotherapy given for head and neck cancer. Radiother Oncol. 30:1994;26-32.
3. Denham J.W., Walker Q.J., Lamb D.S., et al. Mucosal regeneration during radiotherapy. Radiother Oncol. 41:1996;109-118.
4. Lockhart P.B. Oral complications of radiation therapy. Peterson D.E., Elias E.G., Sonis S.T. Head and neck management of the cancer patient. 1986;429-449 Martinus Nijhoff, Boston.
5. Fowler J.F., Lindstrom M.J. Loss of local control with prolongation in radiotherapy. Int J Radiat Oncol Biol Phys. 23:1992;457-467.
6. Allison R.R., Vongtama V., Vaughan J., et al. Symptomatic acute mucositis can be minimized or prophylaxed by the combination of sucralfate and fluconazole. Cancer Invest. 13:1995;16-22.
7. Barker G., Loftus L., Cuddy P., et al. The effects of sucralfate suspension and diphenhydramine syrup plus kaolin-pectin on radiotherapy-induced mucositis. Oral Surg Oral Med Oral Pathol. 71:1991;288-293.
8. Carl W., Emrich L.S. Management of oral mucositis during local radiation and systemic chemotherapy A study of 98 patients . J Prosthet Dent. 66:1991;361-369.
9. Epstein J.B., Wong F.L.W. The efficacy of sucralfate suspension in the prevention of oral mucositis due to radiation therapy. Int J Radiat Oncol Biol Phys. 28:1994;693-698.
10. Epstein J.B., Stevenson-Moore P. Benzydamine hydrochloride in prevention and management of pain in oral mucositis associated with radiation therapy. Oral Surg Oral Med Oral Pathol. 62:1986;145-148.
11. Frandsen L., Henriksson R., Littbrand B., Zackrisson B. Effects of sucralfate on mucositis during and following radiotherapy of malignancies in the head and neck region A double-blind placebo-controlled study . Acta Oncol. 34:1995;219-223.
12. Makkonen T.A., Boström P., Vilja P., et al. Sucralfate mouth washing in the prevention of radiation-induced mucositis A placebo-controlled double-blind randomized study . Int J Radiat Oncol Biol Phys. 30:1994;177-182.
13. Meredith R., Salter M., Kim R., et al. Sucralfate for radiation mucositis Results of a double-blind randomized trial . Int J Radiat Oncol Biol Phys. 37:1997;275-279.
14. Pfeiffer P., Hansen O., Madsen E.L., et al. A prospective pilot study on the effect of sucralfate mouth-swishing in reducing stomatitis during radiotherapy of the oral cavity. Acta Oncol. 29:1990;471-473.
15. Lieschke G.J., Burgess A.W. Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor First part . N Engl J Med. 327:1992;28-35.
16. Lieschke G.J., Burgess A.W. Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor Second part . N Engl J Med. 327:1992;99-106.
17. Masucci G, Fernberg J-O, Höglund-Ersin L; et al. Beneficial treatment of radiotherapy induced mucositis with rH-GM-CSF in patients with tumours of the oral cavity/oropharynx (Abstr). In: 6th International Congress on Anti-Cancer Treatment, 6-9 Feb.; Paris; France; 1996. p. 83.
18. Schuchter L.M., Luginbuhl W.E., Meropol N.J. The current status of toxicity protectants in cancer therapy. Semin Oncol. 19:1992;742-751.
19. Masucci G. New clinical applications of granulocyte-macrophage colony-stimulating factor. Med Oncol. 13:1996;149-154.
20. Chi K.-H., Chen C.-H., Chan W.-K., et al. Effect of granulocyte-macrophage colony-stimulating factor on oral mucositis in head and neck cancer patients after cisplatin, fluorouracil, and leucovorin chemotherapy. J Clin Oncol. 13:1995;2620-2628.
21. Gordon B., Spadinger A., Hodges E., et al. Effect of granulocyte-macrophage colony-stimulating factor on oral mucositis after hematopoietic stem-cell transplantation. J Clin Oncol. 12:1994;1917-1922.
22. Kannan V., Bapsy P.P., Anantha N., et al. Efficacy and safety of granulocyte macrophage- colony stimulating factor (GM-CSF) on the frequency and severity of radiation mucositis in patients with head and neck carcinoma. Int J Radiat Oncol Biol Phys. 37:1997;1005-1010.
23. Throuvalas N., Antonadou D., Pullizi M., et al. Evaluation of efficacy and safety of GM-CSF in the prophylaxis of mucositis in patients with head and neck cancer treated with RT. (Abstr) Eur J Cancer. 41A:(Suppl. 7):1997;431.
24. Tarnawski A., Hollander D., Krause W.J., et al. Effect of sucralfate on normal gastric mucosa Histologic, ultrastructural and functional assessment . Gastroenterol. 84:1983;1331.
25. Makkonen T.A., Nordman E. Estimation of long-term salivary gland damage induced by radiotherapy. Acta Oncol. 26:1987;307-312.
26. Netter F.H. Digestive system, part 1 Upper digestive tract . Oppenheimer E. The Ciba collection of medical illustrations. 3rd ed. 1978;14 Ciba, New York.
27. Ferguson D.B. Salivary glands and saliva. Lavelle L.L.B. Applied physiology of the mouth. 1975;145-179 John Wright and Sons Ltd, Bristol.
28. Wang C.C. Radiation therapy for head and neck neoplasms. 3rd ed. 1997;Wiley-Liss, New York.
29. ICRU. Prescribing, recording, and reporting external beam radiation treatments. Revision of ICRU Report 50. Washington, DC: ICRU News 1996;2:16-18.
30. Makkonen T.A., Borthen L., Heimdahl A., et al. Oropharyngeal colonization with fungi and gram-negative bacilli in patients treated with radiotherapy of the head and neck. Br J Oral Maxillofac Surg. 27:1989;334-340.
31. Parvinen T., Larmas M. The relation of stimulated salivary flow rate and pH to lactobacillus and yeast concentrations in saliva. J Dent Res. 60:1981;1929-1935.
32. Vilja P., Krohn K., Tuohimaa P. A rapid and sensitive noncompetitive avidin-biotin assay for lactoferrin. J Immunol Meth. 76:1985;73-83.
33. Heimdahl A., Nord C.-E. Colonization of the oropharynx with pathogenic micro-organisms A potential risk factor for infection in compromised patients . Chemotherapia. 4:1985;186-191.
34. Ellison R.T., Giehl T.J., La Force F.M. Damage of the outer membrane of enteric gram-negative bacteria by lactoferrin and transferrin. Infect Immun. 56:1988;2774-2781.
35. Stuart J., Norell S., Harrington J.P. Kinetic effect of human lactoferrin on the growth of Escherichia coli 0111. Int J Biochem. 16:1984;1043-1047.
36. Soukka T., Tenovuo J., Lenander-Lumikari M. Fungicidal effect of human lactoferrin against Candida albicans. FEMS Microbiol Lett. 90:1992;223-228.
37. Lumikari M., Soukka T., Nurmio S., et al. Inhibition of the growth of Sreptococcus mutans, Sreptococcus sobrinus and Lactobacillus casei by oral peroxidase system in human saliva. Arch Oral Biol. 36:1991;155-160.
38. Kaflas S., Andersson M., Edwardsson S., et al. Human lactoferrin binding to Porphyromonas gingivalis, Prevotella intermedia and Prevotella melaninogenica. Oral Microbiol Immunol. 6:1991;350-355.
39. Tenovuo J, ed. Human saliva: clinical chemistry and microbiology, Vol. II. Boca Raton, FL: CRC Press; 1989. p. 71-75.
40. Tabak L., Mandel I.D., Karlan D., et al. Alterations in lactoferrin in salivary gland disease. J Dent Res. 57:1978;43-47.
41. Mandel I.D. Sialochemistry in diseases and clinical situations affecting salivary glands. CRC Crit Rev Clin Lab Sci. 11:1980;321-366.
42. Makkonen T.A., Tenovuo J., Vilja P., et al. Changes in the protein composition of whole saliva during radiotherapy in patients with oral or pharyngeal cancer. Oral Surg Oral Med Oral Pathol. 62:1986;270-275.
43. Edmonson J.H., Long H.J., Kvols L.K., et al. Can molgramostim enhance the antitumor effects of cytotoxic drugs in patients with advanced sarcomas? Ann Oncol. 8:1997;637-641.
44. Pfeiffer P., Madsen E.L., Hansen O., et al. Effect of prophylactic sucralfate suspension on stomatitis induced by cancer chemotherapy. Acta Oncol. 29:1990;171-173.
45. Jyung R.W., Wu L., Pierce G.F., et al. Granulocyte-macrophage colony-stimulating factor and granulocyte colony-stimulating factor Differential action on incisional wound healing . Surgery. 115:1994;325-334.
46. Cinat G, Mickiewicz E, Alvarez A; et al. Local use of GM-CSF in the treatment of severe mucositis. A preliminary trial. (Abstr. Proc Am Soc Clin Oncol 1997;16:63a.
47. Rovirosa A., Ferre J., Biete A. Granulocyte macrophage-colony-stimulating factor mouthwashes heal oral ulcers during head and neck radiotherapy. Int J Radiat Oncol Biol Phys. 41:1998;747-754.